UroGen Pharma Ltd. URGN
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 188.73M | 140.49M | 109.79M | 96.52M | 94.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 188.73M | 140.49M | 109.79M | 96.52M | 94.24M |
| Cost of Revenue | 17.28M | 14.26M | 12.45M | 11.63M | 10.80M |
| Gross Profit | 171.46M | 126.24M | 97.34M | 84.89M | 83.43M |
| SG&A Expenses | 176.85M | 171.62M | 155.10M | 149.51M | 140.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 255.39M | 248.71M | 234.65M | 228.82M | 216.70M |
| Operating Income | -66.65M | -108.21M | -124.86M | -132.31M | -122.47M |
| Income Before Tax | -98.11M | -138.31M | -153.42M | -161.64M | -150.82M |
| Income Tax Expenses | -472.00K | -5.09M | 78.00K | 3.00M | 4.15M |
| Earnings from Continuing Operations | -97.64 | -133.23 | -153.49 | -164.64 | -154.97 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -97.64M | -133.23M | -153.49M | -164.64M | -154.97M |
| EBIT | -66.65M | -108.21M | -124.86M | -132.31M | -122.47M |
| EBITDA | -66.35M | -107.90M | -124.56M | -132.01M | -122.18M |
| EPS Basic | -1.98 | -2.75 | -3.20 | -3.46 | -3.27 |
| Normalized Basic EPS | -1.25 | -1.78 | -2.00 | -2.11 | -1.98 |
| EPS Diluted | -1.98 | -2.75 | -3.20 | -3.46 | -3.27 |
| Normalized Diluted EPS | -1.25 | -1.78 | -2.00 | -2.11 | -1.98 |
| Average Basic Shares Outstanding | 197.85M | 195.21M | 192.45M | 190.25M | 188.97M |
| Average Diluted Shares Outstanding | 197.85M | 195.21M | 192.45M | 190.25M | 188.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |